Skip to main
TEM

TEM Stock Forecast & Price Target

TEM Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 45%
Buy 27%
Hold 27%
Sell 0%
Strong Sell 0%

Bulls say

Tempus AI Inc has demonstrated robust financial performance, with total revenue growth of 84.7% year-over-year, primarily driven by a remarkable 117.2% increase in Genomics revenue, which reached $252.9 million. The company anticipates further revenue enhancement through higher average selling prices (ASPs) for its xF liquid biopsy assay and the xT CDx test, signaling a shift to more profitable products. Additionally, the expansion of its customer base via additional pharmaceutical contracts in its data and services business supports a positive long-term outlook for the company's financial trajectory.

Bears say

Tempus AI Inc's gross margins in the Data & Other segment decreased to 69.7% in Q3 from 76.8% in the previous year, indicating a concerning trend in profitability. The company has faced significant operational challenges, including a decline in operating cash flow by $168.5 million year-over-year and the presence of $518.8 million in debt, which raises concerns about its ongoing financial viability. Moreover, the risks surrounding lower-than-projected sales growth, regulatory hurdles, and the potential for declining reimbursement rates further exacerbate the already negative outlook for Tempus AI's stock.

TEM has been analyzed by 11 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 27% recommend Buy, 27% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tempus AI Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tempus AI Inc (TEM) Forecast

Analysts have given TEM a Buy based on their latest research and market trends.

According to 11 analysts, TEM has a Buy consensus rating as of Mar 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $79.45, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $79.45, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tempus AI Inc (TEM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.